BKAIF BioKey (Cayman), Inc.
Pharmaceutical Preparations · OTC · SEC CIK 2108359 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets468.5%
Debt / equity—
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2025Q32025-09-30 | 2025Q22025-06-30 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| SG&A expense | $391,175 | $250,154 | $234,033 | $127,109 |
| Operating income | -$391,175 | -$250,154 | -$234,033 | -$127,109 |
| Interest expense | $43,705 | $42,270 | $40,770 | $36,264 |
| Pretax income | -$397,578 | -$268,417 | -$239,758 | -$145,444 |
| Net income | -$397,578 | -$268,417 | -$239,758 | -$145,444 |
| EBITDA | -$386,651 | -$245,522 | -$228,738 | -$120,803 |
| EPS (basic) | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS (diluted) | -0.01 | -0.01 | -0.01 | -0.01 |
| Weighted avg. shares (diluted) | 30.00M | 30.00M | 30.00M | 30.00M |
| Balance sheet | ||||
| Cash & equivalents | $110 | $4,618 | $52,781 | $16,466 |
| Current assets | $27,435 | $59,163 | — | — |
| PP&E, net | $66,068 | $70,592 | — | — |
| Total assets | $1.61M | $1.72M | — | — |
| Current liabilities | $6.31M | $5.96M | — | — |
| Total liabilities | $7.56M | $7.27M | — | — |
| Shareholders' equity | -$5.95M | -$5.55M | -$4.87M | -$4.63M |
| Shares outstanding | 30.00M | 30.00M | — | — |
| Cash flow statement | ||||
| Operating cash flow | -$194,508 | — | -$173,867 | — |
| Financing cash flow | $190,000 | — | $210,182 | — |
| Depreciation & amortization | $4,524 | $4,632 | $5,295 | $6,306 |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.